Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight rating and announces Price Target of $34.
Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.